Top Markets
Coin of the day
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc.

COEP
주식 순위 #28029
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates... Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
주가
$4.81
마지막 동기화: 2026-07-27
시가총액
$29.01M
변동 (1일)
-8.56%
변동 (1년)
-64.66%
국가
US
거래 Coeptis Therapeutics Holdings, Inc. (COEP)

카테고리

Coeptis Therapeutics Holdings, Inc. (COEP)의 매출
Aug 2026 기준 매출 TTM: 0
Coeptis Therapeutics Holdings, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Coeptis Therapeutics Holdings, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B -
US
$2.23B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH